MCID: ANG015
MIFTS: 52

Angioedema malady

Categories: Skin diseases, Genetic diseases, Bone diseases, Immune diseases, Rare diseases

Aliases & Classifications for Angioedema

Aliases & Descriptions for Angioedema:

Name: Angioedema 12 52 42 14 69
Angioneurotic Oedema 12
Angioneurotic Edema 12
Giant Urticaria 12
Quincke's Edema 12

Classifications:



External Ids:

Disease Ontology 12 DOID:1558
ICD10 33 T78.3
MeSH 42 D000799
NCIt 47 C112175
UMLS 69 C0002994

Summaries for Angioedema

Disease Ontology : 12 A skin disease characterized by the rapid swelling of the dermis, subcutaneous tissue, mucosa and submucosal tissues.

MalaCards based summary : Angioedema, also known as angioneurotic oedema, is related to hereditary angioedema and angioedema induced by ace inhibitors, and has symptoms including edema and joint swelling. An important gene associated with Angioedema is SERPING1 (Serpin Family G Member 1), and among its related pathways/superpathways are Collagen chain trimerization and Peptide hormone metabolism. The drugs Omalizumab and Icatibant have been mentioned in the context of this disorder. Affiliated tissues include skin, tongue and endothelial.

Wikipedia : 71 Angioedema is an area of swelling of the lower layer of skin and tissue just under the skin or mucous... more...

Related Diseases for Angioedema

Diseases in the Angioedema family:

Angioedema, Hereditary, Type Iii Angioedema, Hereditary, Types I and Ii
Hereditary Angioedema Acquired Angioedema
Acquired Angioedema Type 1 Acquired Angioedema Type 2

Diseases related to Angioedema via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 147)
id Related Disease Score Top Affiliating Genes
1 hereditary angioedema 12.4
2 angioedema induced by ace inhibitors 12.3
3 angioedema, hereditary, type iii 12.2
4 angioedema, hereditary, types i and ii 12.2
5 acquired angioedema 12.2
6 episodic angioedema with eosinophilia 12.2
7 acquired angioedema type 2 11.8
8 acquired angioedema type 1 11.7
9 c1 inhibitor deficiency 11.7
10 vibratory urticaria 11.5
11 loiasis 10.7
12 carboxypeptidase n deficiency 10.7
13 complement component 4, partial deficiency of 10.7
14 urticaria 10.4
15 acro coxo mesomelic dysplasia 10.2 C1S SERPING1
16 lymph node cancer 10.1 KNG1 SERPING1
17 malignant acth producing neoplasm of pituitary gland 10.1 C1S KNG1 SERPING1
18 secretory diarrhea myopathy and deafness 10.1 ACE KNG1
19 laryngitis 10.0
20 lymphoma 10.0
21 chylocele of tunica vaginalis 10.0 ACE KLKB1 KNG1
22 petrositis 10.0 ACE KLKB1 KNG1
23 charcot-marie-tooth disease 2a2b 9.9 C1S KNG1 PTGS2 SERPING1
24 lupus erythematosus 9.9
25 critical limb ischemia 9.9 ACE KNG1 MME
26 microcystic adenoma 9.9 C1S MME
27 pancreatitis 9.8
28 thyroiditis 9.8
29 systemic lupus erythematosus 9.8
30 endotheliitis 9.8
31 ischemia 9.8
32 dermatitis 9.8
33 acute pancreatitis 9.8
34 artemis deficiency 9.7 BDKRB2 C1S KLKB1 KNG1 SERPING1
35 macroglossia 9.7
36 carcinoid syndrome 9.7
37 arthritis 9.7
38 contact dermatitis 9.7
39 physical urticaria 9.7
40 adult-onset still's disease 9.7
41 fasciitis 9.7
42 leukocyte adhesion deficiency, type iii 9.6 BDKRB2 C1S F12 KLKB1 KNG1 SERPING1
43 allergic urticaria 9.6
44 discoid lupus erythematosus 9.6
45 cheilitis 9.6
46 vasculitis 9.6
47 eosinophilic fasciitis 9.6
48 myelofibrosis 9.6
49 cerebritis 9.6
50 hodgkin lymphoma 9.6

Graphical network of the top 20 diseases related to Angioedema:



Diseases related to Angioedema

Symptoms & Phenotypes for Angioedema

UMLS symptoms related to Angioedema:


edema, joint swelling

Drugs & Therapeutics for Angioedema

Drugs for Angioedema (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 194)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Omalizumab Approved, Investigational Phase 4,Phase 3,Phase 2 242138-07-4
2
Icatibant Approved Phase 4,Phase 3,Phase 2,Phase 1 138614-30-9, 130308-48-4 71364
3
Desloratadine Approved, Investigational Phase 4 100643-71-8 124087
4
Histamine Approved, Investigational Phase 4,Phase 2,Phase 3 75614-87-8, 51-45-6 774
5
Loratadine Approved Phase 4,Phase 2 79794-75-5 3957
6
Zinc Approved Phase 4 7440-66-6 32051 23994
7
Everolimus Approved Phase 4 159351-69-6 6442177
8
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 1 22916-47-8 4189
9
Ramipril Approved Phase 4 87333-19-5 5362129
10
Sirolimus Approved, Investigational Phase 4 53123-88-9 5284616 6436030 46835353
11
Enalapril Approved, Vet_approved Phase 4 75847-73-3 5362032 40466924
12
Enalaprilat Approved Phase 4 76420-72-9 6917719
13
Valsartan Approved, Investigational Phase 4 137862-53-4 60846
14
Bradykinin Phase 4,Phase 3,Phase 2,Phase 1 58-82-2 439201
15 Kininogens Phase 4,Phase 3,Phase 2,Phase 1
16 Vasodilator Agents Phase 4,Phase 3,Phase 2,Phase 1
17 Antibodies Phase 4,Phase 3,Phase 2,Phase 1
18 Immunoglobulins Phase 4,Phase 3,Phase 2,Phase 1
19 Anti-Allergic Agents Phase 4,Phase 3,Phase 2
20 Anti-Asthmatic Agents Phase 4,Phase 3,Phase 2
21 Respiratory System Agents Phase 4,Phase 3,Phase 2
22 Angiotensin-Converting Enzyme Inhibitors Phase 4,Phase 3,Phase 2,Phase 1
23 HIV Protease Inhibitors Phase 4,Phase 3,Phase 2,Phase 1
24
protease inhibitors Phase 4,Phase 3,Phase 2,Phase 1
25 Analgesics Phase 4,Phase 3,Phase 2,Phase 1
26 Analgesics, Non-Narcotic Phase 4,Phase 3,Phase 2,Phase 1
27 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 2,Phase 1
28 Anti-Inflammatory Agents, Non-Steroidal Phase 4,Phase 3,Phase 2,Phase 1
29 Antirheumatic Agents Phase 4,Phase 3,Phase 2,Phase 1
30 Bradykinin B2 Receptor Antagonists Phase 4,Phase 3,Phase 2,Phase 1
31 Bradykinin Receptor Antagonists Phase 4,Phase 3,Phase 2,Phase 1
32 Complement Inactivating Agents Phase 4,Phase 3,Phase 2,Phase 1
33 Complement System Proteins Phase 4,Phase 3,Phase 2,Phase 1
34 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Phase 1
35 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1
36 Complement C1 Inactivator Proteins Phase 4,Phase 3,Phase 2,Phase 1
37 Complement C1 Inhibitor Protein Phase 4,Phase 3,Phase 2,Phase 1
38 Complement C1s Phase 4,Phase 3,Phase 2,Phase 1
39 Antipruritics Phase 4,Phase 3,Phase 2
40 Cholinergic Agents Phase 4
41 Cholinergic Antagonists Phase 4
42 Dermatologic Agents Phase 4,Phase 3,Phase 2,Phase 1
43 Histamine Antagonists Phase 4,Phase 3,Phase 2
44 Histamine H1 Antagonists Phase 4,Phase 3,Phase 2
45 Histamine H1 Antagonists, Non-Sedating Phase 4,Phase 2
46
Histamine Phosphate Phase 4,Phase 2,Phase 3 51-74-1 65513
47 Neurotransmitter Agents Phase 4,Phase 2,Phase 3,Phase 1
48 Hypoglycemic Agents Phase 4
49 insulin Phase 4
50 Insulin, Globin Zinc Phase 4

Interventional clinical trials:

(show top 50) (show all 123)
id Name Status NCT ID Phase
1 A Call Center During HAE Attacks (SOS HAE) Completed NCT01679912 Phase 4
2 Efficacy, Safety and Tolerability of Icatibant for the Treatment of HAE Completed NCT01457430 Phase 4
3 A Study to Evaluate the Safety and Effect of Escalating Doses of CINRYZE Completed NCT00914966 Phase 4
4 Postmarketing Immunogenicity Study in HAE Subjects Treated With Berinert Completed NCT01467947 Phase 4
5 Desloratadine 5, 10 and 20mg in Patients With Cold Urticaria Completed NCT01444196 Phase 4
6 Omalizumab in Chronic Spontaneous Urticaria Patients Non Responding to Initial Standard antihistaminE Treatment Completed NCT02550106 Phase 4
7 Exubera Large Simple Trial To Evaluate Long-Term Pulmonary And Cardiovascular Safety Completed NCT00359801 Phase 4
8 Study Evaluating The Effect Of Ramipril On Urinary Protein Excretion In Renal Transplant Patients Converted To Sirolimus Completed NCT00502242 Phase 4
9 comParIson Of Sacubitril/valsartaN Versus Enalapril on Effect on ntpRo-bnp in Patients Stabilized From an Acute Heart Failure Episode Recruiting NCT02554890 Phase 4
10 Treatment of Idiopathic Angioedema With Xolair as Add-on Therapy Not yet recruiting NCT02966314 Phase 4
11 Effect of Bradykinin Receptor Antagonism on ACE Inhibitor-associated Angioedema Terminated NCT01574248 Phase 4
12 C1-INH Compared to Placebo at the Time of Prodromal Symptoms for Hereditary Angioedema (HAE) Exacerbation Withdrawn NCT01151735 Phase 4
13 C1-Esteraseremmer-N for the Treatment of Hereditary (and Acquired) Angioedema Completed NCT00125151 Phase 3
14 C1-Esteraseremmer-N for the Treatment of Hereditary (and Acquired) Angioedema Completed NCT00125541 Phase 2, Phase 3
15 A Study to Evaluate the Clinical Efficacy and Safety of Subcutaneously Administered C1-esterase Inhibitor in the Prevention of Hereditary Angioedema Completed NCT01912456 Phase 3
16 Impact of Omalizumab on Quality of Life Measures and Angioedema Occurrence in Patients With CSU Refractory to Therapy Completed NCT01723072 Phase 3
17 Safety and Efficacy Study of CINRYZE for Prevention of Angioedema Attacks in Children Ages 6-11 With Hereditary Angioedema Completed NCT02052141 Phase 3
18 Open-Label C1 Esterase Inhibitor (C1INH-nf) for the Treatment of Acute Hereditary Angioedema (HAE) Attacks Completed NCT00438815 Phase 3
19 Blinded Safety & Efficacy Placebo Controlled Study of Icatibant for Angiotensin Converting Enzyme Inhibitor Induced Angioedema Completed NCT01919801 Phase 3
20 Subcutaneous Treatment With Icatibant for Acute Attacks of Hereditary Angioedema Completed NCT00097695 Phase 3
21 Efficacy and Safety Study of DX-2930 to Prevent Acute Angioedema Attacks in Patients With Type I and Type II HAE Completed NCT02586805 Phase 3
22 A Study of Icatibant in Patients With Acute Attacks of Hereditary Angioedema (FAST-3) Completed NCT00912093 Phase 3
23 Safety and Efficacy Study of Repeated Doses of DX-88 (Ecallantide) to Treat Attacks of Hereditary Angioedema (HAE) Completed NCT00456508 Phase 3
24 Open-Label C1 Esterase Inhibitor (C1INH-nf) for the Prevention of Acute Hereditary Angioedema (HAE) Attacks Completed NCT00462709 Phase 3
25 Efficacy Study of DX-88 (Ecallantide) to Treat Acute Attacks of Hereditary Angioedema (HAE) Completed NCT00457015 Phase 3
26 Recombinant Human C1 Inhibitor for the Treatment of Acute Attacks in Patients With Hereditary Angioedema Completed NCT00225147 Phase 2, Phase 3
27 Recombinant Human C1 Inhibitor for the Treatment of Acute Attacks in Patients With Hereditary Angioedema Completed NCT00262301 Phase 3
28 12-Week Safety and Efficacy Study of BCX4161 as an Oral Prophylaxis Against HAE Attacks Completed NCT02303626 Phase 2, Phase 3
29 Subcutaneous Treatment With Icatibant for Acute Attacks of Hereditary Angioedema (HAE) Completed NCT00500656 Phase 3
30 Recombinant Human C1 Inhibitor for the Treatment of Acute Attacks in Patients With Hereditary Angioedema Completed NCT00262288 Phase 2, Phase 3
31 C1 Esterase Inhibitor in Hereditary Angioedema (HAE)(Extension Study) Completed NCT00292981 Phase 3
32 C1 Esterase Inhibitor (C1INH-nf) for the Prevention of Acute Hereditary Angioedema (HAE) Attacks Completed NCT01005888 Phase 3
33 Efficacy and Safety Study of DX-88 to Treat Acute Attacks of Hereditary Angioedema (HAE) Completed NCT00262080 Phase 3
34 Efficacy, Safety and Immunogenicity Study of Recombinant Human C1 Inhibitor for the Treatment of Acute HAE Attacks Completed NCT01188564 Phase 3
35 Berinert P Study of Subcutaneous Versus Intravenous Administration Completed NCT00748202 Phase 3
36 EASSI - Evaluation of the Safety of Self-Administration With Icatibant Completed NCT00997204 Phase 3
37 Human C1 Esterase Inhibitor (C1-INH) in Subjects With Acute Abdominal or Facial Hereditary Angioedema (HAE) Attacks Completed NCT00168103 Phase 2, Phase 3
38 C1 Esterase Inhibitor (C1INH-nf) for the Treatment of Acute Hereditary Angioedema (HAE) Attacks Completed NCT00289211 Phase 3
39 AVE7688 in Patients With Mild to Moderate Blood Pressure Completed NCT00284128 Phase 2, Phase 3
40 OPTIMA: Efficacy of Optimized Re-treatment and Step-up Therapy With Omalizumab in Chronic Spontaneous Urticaria (CSU) Patients Completed NCT02161562 Phase 3
41 Bilastine Updosing in Chronic Spontaneous Urticaria Completed NCT02213367 Phase 3
42 Glucocorticoids With Antihistamines Versus Antihistamines in Acute Urticaria in Emergency Completed NCT02565680 Phase 2, Phase 3
43 A Study to Evaluate the Efficacy, Response Duration and Safety of Xolair (Omalizumab) in Patients With Chronic Idiopathic Urticaria (CIU)/Chronic Spontaneous Urticaria (CSU) Who Remain Symptomatic Despite Antihistamine Treatment (H1) Completed NCT01292473 Phase 3
44 A Study of the Efficacy and Safety of Omalizumab (Xolair) in Patients With Chronic Idiopathic Urticaria (CIU)/Chronic Spontaneous Urticaria (CSU) Who Remain Symptomatic Despite Antihistamine (H1) Treatment Completed NCT01287117 Phase 3
45 A Safety Study of Xolair (Omalizumab) in Patients With Chronic Idiopathic Urticaria (CIU) Who Remain Symptomatic Despite Treatment With H1 Antihistamines, H2 Blockers, and/or Leukotriene Receptor Antagonists Completed NCT01264939 Phase 3
46 Randomized, Double-blind, Two Arms, Multicenter, Phase III Study of Berinert for Treatment of ACE Induced Angioedema Recruiting NCT01843530 Phase 3
47 Combination Antibiotic Therapy for Methicillin Resistant Staphylococcus Aureus Infection Recruiting NCT02365493 Phase 3
48 Long-term Safety and Efficacy Study of DX-2930 to Prevent Acute Angioedema Attacks in Patients With Type I and Type II HAE Active, not recruiting NCT02741596 Phase 3
49 A Pharmacokinetic, Tolerability and Safety Study of Icatibant in Children and Adolescents With Hereditary Angioedema Active, not recruiting NCT01386658 Phase 3
50 Study to Evaluate the Clinical Efficacy and Safety of Subcutaneously Administered C1 Esterase Inhibitor for the Prevention of Angioedema Attacks in Adolescents and Adults With Hereditary Angioedema Active, not recruiting NCT02584959 Phase 3

Search NIH Clinical Center for Angioedema

Inferred drug relations via UMLS 69 / NDF-RT 48 :


Cochrane evidence based reviews: angioedema

Genetic Tests for Angioedema

Anatomical Context for Angioedema

MalaCards organs/tissues related to Angioedema:

39
Skin, Tongue, Endothelial, Thyroid, Testes, B Cells, Heart

Publications for Angioedema

Articles related to Angioedema:

(show top 50) (show all 1274)
id Title Authors Year
1
Recurrent angioedema associated with pharmacological inhibition of dipeptidyl peptidase IV. ( 28073873 )
2017
2
Clinical characteristics in cholinergic urticaria with palpebral angioedema: Report of 15 cases. ( 27876252 )
2017
3
Treatment for hereditary angioedema with normal C1-INH and specific mutations in the F12 gene (HAE-FXII). ( 27905115 )
2017
4
Manifestations of hereditary angioedema. ( 28007084 )
2017
5
A Case of Miller Fisher Syndrome, Thromboembolic Disease, and Angioedema: Association or Coincidence? ( 28090073 )
2017
6
Glucocorticoid receptor gene polymorphisms in hereditary angioedema with C1-inhibitor deficiency. ( 28069032 )
2017
7
A Case of Type 2 Hereditary Angioedema With SERPING1 Mutation. ( 27826968 )
2017
8
Short-term prophylactic use of C1-inhibitor concentrate in hereditary angioedema: Findings from an international patient registry. ( 27865714 )
2017
9
Current and future therapies for the treatment of histamine-induced angioedema. ( 28081650 )
2017
10
Computational Modeling of Tracheal Angioedema due to Swelling of the Submucous Tissue Layer. ( 28052555 )
2017
11
Complements Are Not Always a Good Thing: Novel Therapies for Angioedema. ( 27139131 )
2016
12
Subcutaneous administration of human C1 inhibitor with recombinant human hyaluronidase in patients with hereditary angioedema. ( 27931305 )
2016
13
Prophylactic treatment with plasma-derived C1-inhibitor in idiopathic non-histaminergic angioedema. ( 27145263 )
2016
14
Rituximab in a patient with splenic marginal zone lymphoma and acquired angioedema. ( 27017557 )
2016
15
Racecadotril + ACE inhibitors: angioedema. ( 27213193 )
2016
16
Copy number variation in ALOX5 and PTGER1 is associated with NSAIDs-induced urticaria and/or angioedema. ( 26959713 )
2016
17
Orolingual angioedema to alteplase. Identify, counsel and monitor at risk patients. ( 27591036 )
2016
18
Positive impact of omalizumab on angioedema and quality of life in patients with refractory chronic idiopathic/spontaneous urticaria: analyses according to the presence or absence of angioedema. ( 27911016 )
2016
19
How we manage persons with hereditary angioedema. ( 27071490 )
2016
20
Psychometric Field Study of Hereditary Angioedema Quality of Life Questionnaire for Adults: HAE-QoL. ( 26969268 )
2016
21
Management of Children With Hereditary Angioedema Due to C1 Inhibitor Deficiency. ( 27940765 )
2016
22
The isolated human umbilical vein as a bioassay for kinin-generating proteases: an in vitro model for therapeutic angioedema agents. ( 27165535 )
2016
23
It's Not Always What It Seems: Necrotizing Fasciitis Mimicking Angioedema. ( 27072731 )
2016
24
A Female with Hereditary Angioedema Developing Wheals: A Case Report. ( 27350434 )
2016
25
Noscapine: angioedema. ( 27213192 )
2016
26
Atrial natriuretic peptide as a novel biomarker of hereditary angioedema. ( 26960949 )
2016
27
Effect of bradykinin receptor antagonism on ACE inhibitor-associated angioedema. ( 27913306 )
2016
28
Ofloxacin Induced Angioedema: A Rare Adverse Drug Reaction. ( 28050397 )
2016
29
Tamoxifen may cause life-threatening angioedema attacks in patients with hereditary angioedema. ( 27878882 )
2016
30
First report of icatibant treatment in a pregnant patient with hereditary angioedema. ( 27093898 )
2016
31
A Novel Approach to the Treatment of Orolingual Angioedema After Tissue Plasminogen Activator Administration. ( 27174372 )
2016
32
Estimation of EuroQol 5-Dimensions health status utility values in hereditary angioedema. ( 27660419 )
2016
33
Diagnostic utility of challenge procedures for physical urticaria/angioedema syndromes: a systematic review. ( 27585061 )
2016
34
Hereditary angioedema: A rare cause of pancreatitis. ( 27576199 )
2016
35
Hereditary Angioedema: Death after a Dental Extraction. ( 27491932 )
2016
36
A case of acquired angioedema possibly associated with adenocarcinoma of the colon. ( 27026513 )
2016
37
C1-esterase inhibitor for short-term prophylaxis in a patient with hereditary angioedema with normal C1 inhibitor function. ( 27871580 )
2016
38
International consensus on the diagnosis and management of pediatric patients with hereditary angioedema with C1 inhibitor deficiency. ( 27503784 )
2016
39
Shortened Activated Partial Thromboplastin Time May Help in Diagnosing Hereditary and Acquired Angioedema. ( 27463190 )
2016
40
Carbamazepine-induced angioedema. ( 27999472 )
2016
41
Self-administered C1 esterase inhibitor concentrates for the management of hereditary angioedema: usability and patient acceptance. ( 27660422 )
2016
42
Acute Angioedema in a Patient Who Received Ketamine and Succinylcholine: A Case Report. ( 27625106 )
2016
43
Assessment of inhibitory antibodies in patients with hereditary angioedema treated with plasma-derived C1 inhibitor. ( 27788880 )
2016
44
New mutations in SERPING1 gene of Brazilian patients with hereditary angioedema. ( 26812872 )
2016
45
Genetics of Hereditary Angioedema Revisited. ( 27116602 )
2016
46
Catabolism of C1 inhibitor influences the response to replacement therapy in hereditary angioedema. ( 28025012 )
2016
47
Hereditary angioedema with F12 mutation: Clinical features and enzyme polymorphisms in 9 Southwestern Spanish families. ( 27788882 )
2016
48
Drug-induced non-immune-mediated angioedema. ( 27152403 )
2016
49
High attack frequency in patients with angioedema due to C1-inhibitor deficiency is a major determinant in switching to home therapy: a real-life observational study. ( 27686124 )
2016
50
Efficacy of Omalizumab in a Patient with Angioedema Clinically Resembling a Hereditary Angioedema. ( 27274639 )
2016

Variations for Angioedema

ClinVar genetic disease variations for Angioedema:

6
id Gene Variation Type Significance SNP ID Assembly Location
1 F12 NM_000505.3(F12): c.983C> G (p.Thr328Arg) single nucleotide variant Pathogenic rs118204456 GRCh37 Chromosome 5, 176831232: 176831232
2 SYTL2 NM_032943.4(SYTL2): c.890delG (p.Ser297Thrfs) deletion Pathogenic rs1057519445 GRCh38 Chromosome 11, 85734436: 85734436

Expression for Angioedema

Search GEO for disease gene expression data for Angioedema.

Pathways for Angioedema

Pathways related to Angioedema according to GeneCards Suite gene sharing:

id Super pathways Score Top Affiliating Genes
1
Show member pathways
12.35 DPP4 F12 KLKB1 KNG1 MME XPNPEP2
2
Show member pathways
11.87 ACE DPP4 MME
3
Show member pathways
11.76 F12 KLKB1 KNG1 SERPING1
4 11.24 BDKRB2 C1S F12 KLKB1 KNG1 SERPING1
5 11.19 F12 KLKB1 SERPING1
6 11.16 F12 KLKB1
7
Show member pathways
11.16 ACE BDKRB2 KNG1 MME
8 11 ACE MME
9 10.82 ACE MME
10 10.75 LTC4S PTGS2

GO Terms for Angioedema

Cellular components related to Angioedema according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.56 ACE C1S DPP4 F12 KLKB1 KNG1
2 blood microparticle GO:0072562 9.33 C1S KNG1 SERPING1
3 extracellular exosome GO:0070062 9.28 ACE C1S DPP4 F12 KLKB1 KNG1

Biological processes related to Angioedema according to GeneCards Suite gene sharing:

(show all 17)
id Name GO ID Score Top Affiliating Genes
1 inflammatory response GO:0006954 9.83 BDKRB2 KLKB1 KNG1 PTGS2
2 blood coagulation GO:0007596 9.71 F12 KLKB1 KNG1 SERPING1
3 proteolysis GO:0006508 9.7 ACE C1S DPP4 F12 KLKB1 MME
4 blood circulation GO:0008015 9.57 BDKRB2 SERPING1
5 arachidonic acid secretion GO:0050482 9.56 ACE BDKRB2
6 regulation of vasoconstriction GO:0019229 9.55 ACE BDKRB2
7 vasodilation GO:0042311 9.54 BDKRB2 KNG1
8 lipoxygenase pathway GO:0019372 9.51 LTC4S PTGS2
9 beta-amyloid metabolic process GO:0050435 9.49 ACE MME
10 angiotensin maturation GO:0002003 9.48 ACE MME
11 zymogen activation GO:0031638 9.46 F12 KLKB1
12 negative regulation of intrinsic apoptotic signaling pathway in response to osmotic stress GO:1902219 9.43 BDKRB2 PTGS2
13 fibrinolysis GO:0042730 9.43 F12 KLKB1 SERPING1
14 positive regulation of fibrinolysis GO:0051919 9.37 F12 KLKB1
15 Factor XII activation GO:0002542 9.32 F12 KLKB1
16 hemostasis GO:0007599 9.26 F12 KLKB1 KNG1 SERPING1
17 blood coagulation, intrinsic pathway GO:0007597 8.92 F12 KLKB1 KNG1 SERPING1

Molecular functions related to Angioedema according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 hydrolase activity GO:0016787 9.8 ACE C1S DPP4 F12 KLKB1 MME
2 serine-type endopeptidase activity GO:0004252 9.62 C1S DPP4 F12 KLKB1
3 metallopeptidase activity GO:0008237 9.54 ACE MME XPNPEP2
4 aminopeptidase activity GO:0004177 9.4 DPP4 XPNPEP2
5 serine-type peptidase activity GO:0008236 9.26 C1S DPP4 F12 KLKB1
6 peptidase activity GO:0008233 9.17 ACE C1S DPP4 F12 KLKB1 MME
7 exopeptidase activity GO:0008238 9.16 ACE MME

Sources for Angioedema

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....